<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01163071</url>
  </required_header>
  <id_info>
    <org_study_id>CA601</org_study_id>
    <nct_id>NCT01163071</nct_id>
  </id_info>
  <brief_title>A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas</brief_title>
  <official_title>A Phase I Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the MTD and/or RP2D of ABI-011 when administered by
      IV on Day 1, Day 8 and Day 15 with one week of rest for patients with advanced solid tumor
      malignancies and lymphomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dose limiting toxicities (DLT), maximum tolerated dose (MTD)
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DLT's and MTD Safety and Toxicity profile</measure>
    <time_frame>During Cycle 1, treatment period, End of Study and Follow-Up, approximately up to 2 years</time_frame>
    <description>Evaluate PK and PD of ABI-011. Preliminary assessment of tumor response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and toxicity profile of repeated dosing of ABI-011</measure>
    <time_frame>End of study and follow up, approximately up to 2 years</time_frame>
    <description>Number of subjects with Adverse Events; laboratory assessments, ECG assessments, opthalmologic assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate plasma PK of ABI-011 on this schedule</measure>
    <time_frame>End of Study and follow-up, Up to two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess biological activity and PD of ABI-011</measure>
    <time_frame>End of study and follow-up, approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Make preliminary assessment of tumor response</measure>
    <time_frame>End of study and follow-up, approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess biological activity/exploratory during treatment C1, C2, EOS</measure>
    <time_frame>End of Study and follow-up, aproximately two years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>ABI-011</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABI-011</intervention_name>
    <description>ABI-011</description>
    <arm_group_label>ABI-011</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be equal or greater 18 years of age

          -  ECOG performance status less than or equal to 2 (Appendix 2)

          -  Pts. must be willing and able to sign informed consent

          -  Cytologically or histologically confirmed solid tumor malignancy or lymphoma for which
             no standard approved therapy is available. Patients should have accessible tumor
             lesions amendable to 2 serial biopsies which would not put the patient or their
             treatment at risk

          -  Pt. agrees and is willing to provide 2 serial tumor biopsies(optional on first phase,
             mandatory on 2nd phase)

          -  During the dose escalation phase, measurable or non-measurable disease as defined by
             RECIST criteria. At 2nd phase, only patients with measurable disease

          -  Life expectancy of equal or greater than 12 weeks

          -  All AEs of any prior chemotherapy, surgery or radiotherapy, must have resolved to
             grade equal to or less than 1

          -  The following laboratory results must be present within 14 days of initial ABI-011
             administration

               -  Hemoglobin greater or equal to 9g/dL

               -  Absolute neutrophils count(ANC)greater or equal to 1.5 x 10^9/L

               -  Platelet count is greater or equal to 100 x 10^9/L

               -  Serum bilirubin less than or equal to 1.5 x upper limit of normal (ULN)

               -  Aspartate transaminase (AST) and alanine transaminase (ALT)is less than or equal
                  to 2.5 ULN(except if liver metastases are present; then values must be less than
                  or equal to 5 x ULN)

               -  Potassium, corrected calcium and magnesium WNL

               -  Serum Creatinine less than or equal to 1.5 x ULN

               -  Activated aPTT,PT,INR,WNL

               -  WNL levels : Troponin I and T, CK-MB,BNP

          -  At least one measurable lesion should be evaluable (DCE-MRI eligibility criteria)and
             meet at least one of the criteria below:

               -  At least one measurable lesions should be at least 3 cm in diameter and should
                  not be near the diaphragm or mediastinum

               -  Lesions should be solid masses that enhance with contrast, without signs of
                  calcification on the most recent computed tomography (CT) or magnetic resonance
                  (MRI)scan

          -  Pts. must be willing to practice contraceptive methods for the duration of the study
             and for one month following study completion. Female patients must be postmenopausal,
             surgically sterile or they must agree to use acceptable methods of birth control. Male
             patients must be surgically sterile or agree to use an acceptable method of
             contraception.

          -  Women of childbearing potential must have a negative serum pregnancy test(B-hCG)within
             72 hours prior to first study drug administration

        Exclusion Criteria:

          -  Inability to comply with study and follow-up procedures

          -  Women who are pregnant or lactating

          -  Treatment with chemotherapy, hormonal therapy(except leuprolide for prostate cancer),
             immunotherapy, biologic therapy, or radiation therapy as cancer therapy within 4 weeks
             before initiation of study treatment. Six weeks should have elapsed if prior
             chemotherapy treatment included nitrosoureas or mitomycin C

          -  Pts. who have received antibody-based therapies within 28 days or 5 half-lives of the
             agent, whichever time period is longer

          -  Major surgery within 6 weeks before first study drug administration

          -  Prior treatment with tumor vascular disruptive agents

          -  Any uncontrolled medical or psychiatric risk factors

          -  Central nervous system(CNS)metastases.

          -  History of diabetic retinopathy. All patients must be evaluated by an ophthalmologist
             prior to study treatment

          -  Any history of myopathy, either peripheral or cardiac

          -  Current use of medications that may have the potential of QTc prolongation

          -  History of allergy or hypersensitivity to any compound of the ABI-011 formulation

          -  Active uncontrolled bacterial, viral, or fungal infection, requiring systemic therapy

          -  Pt.has known infection with human immunodeficiency virus (HIV),or known chronic
             Hepatitis B or Hepatitis C

          -  Inability to be venipunctured and/or tolerate venous access

          -  History of other carcinoma within past 5 years

          -  Pts. requiring therapeutic anticoagulation with either coumadin or low molecular
             weight heparin or with history of any bleeding diathesis. Low dose aspirin and low
             dose coumadin for catheter maintenance are allowed

          -  Lung tumors in a central position.

          -  Cardiac exclusion criteria:

               -  Left ventricular ejection fraction (LVEF)&lt; 50% by echocardiography;

               -  Previous history of MI or ischemic heart disease

               -  EKG findings suggestive of current or previous ischemic heart disease, including
                  left bundle branch block

               -  Prior treatment with chemotherapy agents known to potentially cause
                  cardiotoxicity

               -  Class III or IV heart failure as defined by the New York Heart(NYHA) functional
                  classification

               -  Congenital or acquired long QT syndrome

               -  Uncontrolled hypertension

               -  Current or past history of clinically significant arrhythmias

               -  QTc prolongation

               -  HO Symptomatic PVD (Venous or arterial)

          -  Seizure disease requiring current anticonvulsant treatment

          -  HO previous CVA or TIA

          -  HO inflammatory bowel disease (active or past) or active PUD

          -  HO previous, whole abdomen radiation therapy or more than Grade 1 residual toxicity
             from previous radiation therapy.

          -  History of autoimmune disease or vascular disease (venous or arterial)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia M LoRusso, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karmanos Cancer Institute Hudson-Webber Cancer Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Sarantopoulos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Therapy Research Center at the University Health Sciences Center at San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karmanos Cancer Center Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTRC @ The Utah Health Science Center @ San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2010</study_first_submitted>
  <study_first_submitted_qc>July 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2010</study_first_posted>
  <last_update_submitted>November 3, 2011</last_update_submitted>
  <last_update_submitted_qc>November 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

